VAD Therapy 20/20: Moving Beyond the Myopic View of a Nascent Therapy
Overview
Overview
Journal
Ann Cardiothorac Surg
Publisher
AME Publishing Company
Date
2014 Dec 17
PMID
25512902
Citations
1
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.
Citing Articles
Tan N, Sangaralingham L, Schilz S, Dunlay S J Am Heart Assoc. 2017; 6(10).
PMID: 28974501 PMC: 5721829. DOI: 10.1161/JAHA.117.005776.
References
1.
Kirklin J, Naftel D, Kormos R, Stevenson L, Pagani F, Miller M
. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant. 2013; 32(2):141-56.
DOI: 10.1016/j.healun.2012.12.004.
View
2.
Starling R, Moazami N, Silvestry S, Ewald G, Rogers J, Milano C
. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2013; 370(1):33-40.
DOI: 10.1056/NEJMoa1313385.
View
3.
Steinberg B, Piccini J
. Anticoagulation in atrial fibrillation. BMJ. 2014; 348:g2116.
PMC: 4688652.
DOI: 10.1136/bmj.g2116.
View
4.
Kirklin J, Naftel D, Pagani F, Kormos R, Stevenson L, Blume E
. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant. 2014; 33(6):555-64.
DOI: 10.1016/j.healun.2014.04.010.
View
5.
Felker G, Rogers J
. Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. J Am Coll Cardiol. 2006; 47(5):930-2.
DOI: 10.1016/j.jacc.2005.09.070.
View